Gilead and Galapagos report updated safety information for Filgotinib in rheumatiod arthritis

Friday, March 29, 2019

Gilead Sciences and Galapagos announced interim safety information from four studies of the investigational compound filgotinib for the treatment of rheumatoid arthritis (RA). The data include 24 week results of the ongoing Phase 3 FINCH 1, 2, and 3 trials, and updated Week 156 safety data from the Phase 2b DARWIN 3 long term extension study in patients with RA.

Read more

Biotech Training Facility: unique professional GMP and biosafety courses in a state-of-the-art environment.